331 results about "Interstitial fluid" patented technology

Aspects of the current subject matter are directed to a wearable analyte monitoring device with an integrated applicator for deployment of a microneedle array-based sensor into a skin surface of a subject. The microneedle array is retained within a housing body of the wearable analyte monitoring device in a first, loaded configuration. Upon actuation, a biasing element accelerates the microneedle array into the skin of the subject, transitioning the microneedle array to a second, deployed configuration in which the microneedle array protrudes through a distal opening of the housing body and enabling sensing by the microneedle array of one or more target analytes in dermal interstitial fluid of the subject.

A sensor system for optical detection of multiple analytes is discussed. An example system is presented that includes a plurality of lenses configured to receive individual light signals from analyte-sensing chromophores disposed on an array when the analyte-sensing chromophores are illuminated by light while being exposed to different specific analytes within an interstitial fluid. The system further includes at least one volume phase grating (VPG) communicatively coupled to at least one of the plurality of lenses and a detector communicatively coupled to the at least one VPG so that light signals from the analyte-sensing chromophores are focused by the plurality of lenses to the at least one VPG and transmitted to the detector. The detector being operable to generate spectra with each spectrum corresponding to an individual light signal from a single analyte-sensing chromophore.

The invention discloses a craniocerebral injury degree diagnosis auxiliary system based on a medical image, and relates to the technical field of medical treatment, a primary judgment module can accurately judge whether a patient has the risk of interstitial encephaledema or not by analyzing the accumulation degree of interstitial fluid in white matter and quantitatively calculating a penetration anomaly coefficient Syxs, the ability of early risk screening is provided, and the risk of interstitial encephaledema can be accurately judged. Potential problems can be recognized in time before disease deterioration, a clinician is prompted to intervene rapidly, and therefore the prognosis effect of a patient is remarkably improved. When the risk of interstitial encephaledema exists, the type diagnosis module further distinguishes lesion types (such as brain contusion or other injuries) by extracting related distinguishing features in a multi-modal feature set, calculates a locking coefficient Sdxs, and provides a scientific quantitative basis for diagnosis of lesion types based on specific features of the lesions. According to the accurate type diagnosis method, diagnosis errors can be reduced, and reliable support is provided for clinical decision making.

The invention relates to the technical field of biomedical sensing and health monitoring, and discloses a noninvasive glucose detection system. The system comprises an interstitial fluid extraction device, a photoelectric sensing module and a main control circuit which are integrated on a flexible substrate. The interstitial fluid extraction device drives subcutaneous interstitial fluid to migrate to the hydrogel interface layer under the action of reverse ion electroosmosis; the photoelectric sensing module receives interstitial fluid through a hydrogel interface layer, a working electrode of the photoelectric sensing module comprises a Cu monatomic imprinting recognition layer, and imprinting holes formed by Cu monatomic sites are specifically coordinated with glucose molecules. The master control circuit controls sampling and determines the glucose concentration based on the photocurrent signal. Noninvasive sampling and monatomic imprinting photoelectric detection are fused, sampling-detection integration is achieved, and the device has the advantages of being noninvasive, painless, high in selectivity, high in interference resistance, comfortable to wear and the like and is suitable for continuous monitoring of blood glucose.

Systems, methods, and devices feature a wearable device that includes a set of needles sized for access to interstitial fluid. The wearable device also includes a chemical indicator associated with each needle. A concentration of an analyte within the interstitial fluid can be determined based on one or more optical properties of the chemical indicator.

The invention discloses a method and system for reducing data errors of a dynamic glucometer, and the method comprises the steps: collecting a current signal of fluid between subcutaneous tissues in real time through an implantable sensor, and synchronously recording the working environment parameters of the sensor; carrying out denoising and normalization processing on the current signal, and carrying out temperature compensation and drift correction on the signal according to a working environment parameter; extracting time sequence features and frequency domain features from the signals processed in the step S2; training a machine learning model based on the time sequence feature data and the frequency domain feature data, wherein the machine learning model is used for predicting the blood glucose concentration and identifying abnormal data points; correcting a model prediction result through residual analysis and weighted adjustment, and performing secondary correction on abnormal data points in combination with event data input by a patient; and outputting the optimized blood glucose data to a terminal display device in a time sequence curve form. Through the process, the influence of abnormal state data on blood glucose monitoring is reduced, and the data stability is improved.

The present disclosure provides a device and system for detecting and / or measuring a constituent of an interstitial fluid from the skin of a subject. The device is a wearable extended gate field effect transistor (EGFET) device comprising a polymeric substrate for fixing to the skin of the subject: an extended gate electrode comprising a first microneedle configured for accessing the interstitial fluid and a first electric contact, wherein the first microneedle and the first electric contact are disposed on the polymeric substrate; and a field effect transistor (FET) associated with the first microneedle through the first electric contact. Further provided are a method for detecting and / or measuring a constituent of an interstitial fluid from the skin of a subject involving the use of the system and a method for fabricating the EGFET device.

The present application provides a sensor device and related methods for electrochemically measuring a substance in a fluid, particularly a bodily fluid, wherein said sensor device comprises one or more electrodes, wherein said one or more electrodes comprise at least a working electrode, a reference electrode and / or a counter electrode, wherein the surface of at least the working electrode is coated with a crosslinked polymer, such as a crosslinked chitosan, a crosslinked PEI, a crosslinked polylysine, and the like. In particular embodiments, the sensor device may comprise a microneedle array comprising a plurality of microneedle electrodes, wherein at least the working microneedle electrode is coated with a crosslinked polymer. The present application further provides a system and related methods for the monitoring of a first substance and delivery of a second substance in the dermal interstitial fluid of a subject, wherein the system comprises the sensor device and a drug delivery system.

The invention provides an electrochemical luminescence MeHA microneedle patch and a preparation method and application thereof.The preparation method comprises the steps that hyaluronic acid is modified into methacrylated hyaluronic acid, MeHA solid powder is obtained after purification, and the MeHA solid powder is mixed with a photoinitiator to form a precursor solution; and pouring into a microneedle mold, centrifuging, drying and carrying out UV crosslinking to obtain the MeHA microneedle patch loaded with ABEI and glucose oxidase. Through the MeHA microneedle patch-SPE electrode integrated design, the integrated operation of skin interstitial fluid in-situ extraction-enzymatic reaction-electrochemical luminescence detection is realized, sample transfer is not needed, the interference of intermediate links is greatly reduced, the detection accuracy and efficiency are remarkably improved, and the device and the method are particularly suitable for clinical real-time monitoring scenes.

The invention provides a flap retractor for breast cancer surgery, and belongs to the technical field of medical instruments. Comprising an arc-shaped frame, third bent parts are arranged at the two ends of the arc-shaped frame, rebound frames are fixedly connected to the inner walls of the two ends of the arc-shaped frame, air bags are installed in the rebound frames, and second connectors are fixedly connected to the outer walls of the air bags; the drainage assembly is used for sucking interstitial fluid at the incision position of the skin flap, and the drainage assembly is connected with the arc-shaped frame and the rebound frame. By arranging the arc-shaped frame, the position of a skin flap incision can be supported and pulled, the skin flap incision is pulled and opened by means of the air bag and the rebound frame, by means of the pulling mode, operation is convenient and labor-saving, an operator does not need to continuously hold and apply force with hands in the actual operation process, manpower and material resources are saved, and the working efficiency is improved. And the size of the opening of the skin flap incision is controlled according to the air filled in the air bag, so that the control of the size of the opening is more stable, and the accuracy is higher.

The utility model relates to the technical field of medical instruments, in particular to a pair of anti-slip rotatable bent three-blade forceps with a suction function for laparoscopic surgery, which comprises a forceps seat, blades, an opening mechanism, a forceps tube, a rotating mechanism, an inner tube, a rotating wheel, a pull rod, a pull wire, a handle and a suction tube, the blade is connected with the clamp seat through an opening mechanism, a rotating opening is formed in the head end of the clamp pipe, the clamp seat is installed on the rotating opening, the inner pipe is located in a pipe cavity of the clamp pipe, a rotating hole is formed in the tail end of the clamp pipe, the inner pipe penetrates through the rotating hole, the head end of the inner pipe is connected with the clamp seat through a rotating mechanism, and the rotating axis of the clamp seat is perpendicular to the rotating axis of the inner pipe. The utility model has the advantages that the front end of the blade is provided with the arc-shaped hook claw, so that deep pelvic tissues can be firmly grasped, and slipping can be effectively avoided; the rotating wheel is operated to adjust the angle of the clamp seat at the rotating opening through the inner pipe and the rotating mechanism, so that the traction effect of the blades is improved; a special suction channel is arranged in the forceps tube and used for sucking smoke, blood and interstitial fluid generated in the operation process.

A point-of-use analysis with biosensors for peripheral body fluids (e.g., saliva, urine and sweat) and interstitial fluid provides measurements that gain insights to the stress response and inflammation. These measurements may be used in a closed-loop approach in which they are analyzed, and a subject's progress is measured and therapy controlled according to that progress. The point-of-use biosensors provide an opportunity to better understand the effects of stress in real-time and during normal life activities. The digital point-of-use biosensor device enable personalized medicine for many disease conditions.

The invention provides a GelMA microneedle patch loaded with chromogenic gold nano bipyramids and a preparation method thereof.The method comprises the steps that citric acid, chloroauric acid and a CTAC solution are mixed, then sodium borohydride is added, and a seed solution is obtained through stirring and standing; mixing chloroauric acid, silver nitrate, hydrochloric acid and CTAB (cetyltrimethyl ammonium bromide), and sequentially adding ascorbic acid and the seed solution to obtain a growth solution; carrying out centrifugation, morphology regulation and chemical etching purification to obtain a chromogenic gold nano bipyramid solution; the preparation method comprises the following steps: reacting gelatin with methacrylic anhydride in PBS, dialyzing and freeze-drying to obtain GelMA; dissolving GelMA in the gold nanoparticle bipyramid solution, and adding a photoinitiator LAP to obtain a mixed precursor solution; and the GelMA microneedle patch loaded with the gold nano bipyramid is prepared through mold casting, centrifugation, ultraviolet light crosslinking and drying demolding. The microneedle extraction and gold nano bipyramid color development integrated scheme is initiated, blood sampling is not needed, the dermis interstitial fluid is extracted in a minimally invasive mode through the microneedle, detection pain and trauma are reduced, the cross infection risk of blood treatment is avoided, and the microneedle microneedle microneedle microneedle microneedle microneedle microneedle microneedle microneedle microneedle microneedle microneedle microneedle microneedle microneedle microneedle microneedle microneedle microneedle microneedle microneedle microneedle microneedle microneedle

The invention discloses an immunoregulation drug delivery system for specifically targeting focus MDSC cells as well as a preparation method and application of the immunoregulation drug delivery system. The delivery system is of a double-layer vesicle structure, an inner-layer vesicle is a polymer vesicle of an antibody targeting MDSC cell surface marker, the outer wall of the inner-layer vesicle is positively charged and loads an immunoregulation therapeutic gene, and a therapeutic drug is loaded in the inner-layer vesicle; the outer-layer vesicle is an enzyme substrate polypeptide-PEG (Polyethylene Glycol) modified liposomal vesicle which can be disintegrated in a targeted manner under the action of a placenta interstitial fluid high-expression enzyme. The delivery system provided by the invention can realize regulation and control of MDSC in the placenta and regulation and control of immunity in the placenta, avoids influence on functions of other cells in the placenta, can effectively reduce medicine leakage through maternal and fetal barriers, and reduces toxicity to fetuses and maternal bodies.

The invention discloses a high-strength microneedle with directional holes for biological analysis sampling and a preparation method of the high-strength microneedle, and belongs to the technical field of microneedles, the method comprises the following steps: filling a silk fibroin solution into a microneedle mold to form a microneedle preform, the microneedle preform comprising a needle body part and a backing part; performing directional freezing on the microneedle preform to enable ice crystals to directionally grow in the direction from the backing part to the needle body part, and demolding to obtain a frozen blank; the frozen blank is placed in an organic solution of a cross-linking agent, soaked at the low temperature lower than 0 DEG C for ice template low-temperature solvent exchange-cross-linking treatment, taken out and cleaned, then soaked in a salt solution for salting-out treatment strengthening, taken out and cleaned and freeze-dried, and the high-strength microneedle with the directional holes is obtained. The microneedle prepared through the method has high strength and excellent puncture performance, and the skin interstitial fluid collection speed and efficiency are greatly improved.

The invention discloses a self-driven diagnosis and treatment integrated microneedle array paper-based chip as well as a preparation method and application thereof, and belongs to the technical field of biomedicine. The microneedle array chip system comprises a function integration module which at least comprises a self-powered extraction unit, a sensing detection unit and a controlled drug delivery unit. According to the microneedle array paper-based chip, biomarkers in skin interstitial fluid are efficiently collected based on a self-powered thermoelectric chemical battery microneedle, PtPB (at) PEG (at) HA nanoparticles loaded on an immunochromatography test strip combination pad are triggered to be subjected to ring opening, a hybridization chain reaction is induced to generate DNA nano-enzyme, and TMB is catalyzed to develop color; the open-loop nanoparticles can be used for SERS cross detection of biomarkers, and can be used as a thermal initiator to activate the phase change microneedle under the irradiation of near-infrared light, so that drugs are released as required, and precise treatment is realized. Besides, objective quantitative analysis of color signals is realized by constructing a convolutional neural network model, and the system has the functions of naked eye screening, intelligent quantification and personalized treatment, and can improve the home management ability of early skin cancer.

The invention discloses a hydrogel microneedle patch for noninvasive blood glucose detection as well as a preparation method and application of the hydrogel microneedle patch. According to the invention, the microneedle patch is prepared by a turnover technology and is noninvasively applied to the skin surface, so that simple and rapid extraction of interstitial fluid in vivo and a new method for real-time, rapid and quantitative detection of blood glucose in vivo are realized. The hydrogel microneedle patch contains two hydrogel components: one hydrogel component is hydrogel which can be cured and formed by ultraviolet light, and the other hydrogel component is hydrogel which can be cured and formed by ultraviolet light; and the other hydrogel is functional hydrogel with pH responsiveness, and glucose oxidase is added, so that the hydrogel can sensitively react to in-vivo glucose. The double-response hydrogel is jointly mixed and prepared into a microneedle patch form, the microneedle patch is endowed with noninvasive / minimally invasive property when applied to the skin surface, the microneedle patch is very suitable for extraction of interstitial fluid in vivo, and then real-time, rapid and accurate detection of the blood glucose level in vivo is achieved.

A sensor (e.g., an optical sensor) that may be implanted within a living animal (e.g., a human) and may be used to measure an analyte (e.g., glucose or oxygen) in a medium (e.g., interstitial fluid, blood, or intraperitoneal fluid) within the animal. The sensor may include a sensor housing, an analyte indicator covering at least a portion of the sensor housing, and one or more compounds containing boronate or boronic acid moieties that reduce degradation of the analyte indicator.

The invention discloses a plasma concentration detection method, and belongs to the field of biomedical detection.The plasma concentration detection method comprises the steps that a saliva sample and a mesenchymal fluid sample of a to-be-detected object are synchronously collected through non-invasive equipment and minimally invasive equipment, and after centrifugation and membrane filtration pretreatment, the saliva sample and the mesenchymal fluid sample are obtained; a multi-channel biosensor is used for detecting drug metabolite concentrations in saliva and interstitial fluid respectively, a blood drug concentration predicted value is further calculated through a composite calibration model, the model is constructed based on a random forest algorithm, saliva and interstitial fluid concentration data are input, the blood drug concentration is output, and dynamic correction is conducted through species characteristic parameters. Wherein species parameters are obtained in real time through near infrared spectrum, weight coefficients (alpha and beta) are optimized in combination with a multiple regression equation, and finally high-precision prediction is achieved through a weighting algorithm. The method has the advantages of non-invasiveness, cross-species universality, dynamic adaptive correction and the like, and is suitable for clinical monitoring, veterinary medicine and pharmacokinetic research.

The invention relates to a microneedle patch, a preparation method thereof and a blood glucose colorimetric detection method, and belongs to the technical field of biomedicine. The microneedle patch comprises a needle tip layer and a backing layer, the needle tip layer is a methacrylated natural biopolymer matrix in which immobilized enzyme is uniformly distributed, and the backing layer is a methacrylated natural biopolymer matrix in which a chromogenic substrate is uniformly distributed, the immobilized enzyme is composed of a zinc-based imidazoline metal organic framework MAF-7 carrier and a natural enzyme loaded in the framework. The immobilized enzyme with double-enzyme activity is loaded into the needle tip, the spatial distance of the cascade catalytic reaction is limited in the metal organic framework, the mass transfer efficiency is high, the reaction is rapid, the natural enzyme is encapsulated in the metal organic framework MAF-7, and the stability of the enzyme is enhanced; according to the method, color development is carried out by firstly extracting the interstitial fluid and then dropwise adding the color development substrate, the color development effect is obvious, and the time is shorter.

The present disclosure refers to an in vivo analyte sensor, comprising: a substrate (20); a conductive layer (21) disposed over at least a portion of the substrate (20); a sensing layer (24) disposed formed on the conductive layer (21), wherein the sensin\g layer (24) forms a sensing area configured to generate one or more signals identifying a monitored analyte level after insertion of the analyte sensor and when maintained in fluid contact with interstitial fluid; and a membrane layer (25) formed at least on the sensing layer (24). The sensing layer (24) is formed with an area sensitivity of 0,2 to 1,5 nA / (mqx / dL) mm2 within the sensing area. Further, a method of manufacturing an in vivo analyte sensor is provided.

Lymphedema is characterized by the accumulation of protein-rich interstitial fluid, lipids and a significant inflammatory cell infiltrate in the limb. It causes a significant morbidity and is a common disabling disease affecting more than 250 million people worldwide, however there is no curative treatment for lymphedema. Here, the inventors found that dermolipectomies from patient with lymphedema exhibit inflamed gene expression profile compared to normal arm on same patient. After lipidomic analysis, the inventors identified severe decrease in arachidonic acid-derived lipid mediators generated by the 15-lipoxygenase (15-LOX) in lymphedematous arms. Using a mouse model of lymphedema, they reproduced the etiology of the human pathology including the loss of specialized pro-resolving lipid mediators that play essential roles in resolution of inflammation. This was associated with a lack of regulatory T cells (Treg) recruitment in the injured limb adipose tissue. Importantly, the inventors identified the lymphatic endothelial 15-LOX was responsible for the chemoattraction and transendothelial migration of Tregs. These results were confirmed by an aggravation of lymphedema and deterioration of the lymphatic network in an original transgenic mouse model in which ALOX15 gene is selectively deleted in the lymphatic system. Importantly, this was reversed by the injection of 15-LOX expressing lentivectors. These results provide evidence that lymphatic lipoxygenase may represent a novel therapeutic target for lymphedema by serving as a mediator of Treg invasion into lymphedematous adipose tissue.

A sensor (e.g., an optical sensor) that may be implanted within a living animal (e.g., a human) and may be used to measure an analyte (e.g., glucose or oxygen) in a medium (e.g., interstitial fluid, blood, or intraperitoneal fluid) within the animal. The sensor may include a sensor housing, an analyte indicator covering at least a portion of the sensor housing, and one or more compounds having dithio-, thio- or mercapto-containing moieties that reduce degradation of the analyte indicator.

The invention provides a methylation marker for risk assessment of prostatic cancer and application of the methylation marker, and relates to the technical field of molecular biomedicine. The invention provides a methylation marker for early non-invasive identification of prostatic cancer and a combination thereof, and a new marker group related to identification of prostatic cancer is identified based on methylation sequencing data analysis of measured tissue interstitial fluid and urine EV DNA samples of prostatic cancer patients and cancer-free patients. The marker group can effectively distinguish benign and malignant prostate cancer or distinguish inert prostate cancer and highly invasive prostate cancer, a new biomarker is provided for prostate cancer identification, and compared with the previously reported and used technical means, the marker group can more sensitively detect the methylation change of related genes of prostate cancer, and has a good application prospect. More favorable evidence is provided for early diagnosis of the prostate cancer, and a new method is provided for early diagnosis of the prostate cancer.

Systems, devices, and methods for biomonitoring are disclosed herein. In some embodiments, a device for monitoring a user's health comprises a patch including a substrate configured to couple to the user's skin, and an array of microneedles carried by the substrate. The array of microneedles can be configured to access interstitial fluid in the user's skin and generate a first electrical signal indicative of at least one analyte in the interstitial fluid. The device can include a pod configured to releasably couple to the patch, the pod having at least one sensor configured to generate a second electrical signal indicative of a physiological parameter of the user. The pod can further include a processor configured to receive and process the first and second electrical signals to generate health measurements for the user. The pod can also include a communication unit configured to transmit the health measurements to a remote device.

The invention discloses a microneedle array electrochemical sensor for monitoring a sepsis marker C-reactive protein in skin interstitial fluid. According to the novel-arrangement cactus-like structure microneedle array electrode, the enrichment efficiency of detection liquid is remarkably improved through the design that the structure sequentially extends from the center to the periphery, and good attachment to skin tissue is achieved in combination with a flexible substrate material. Electrode interface construction of the electrochemical sensor is based on electrochemical deposition, a C-reactive protein aptamer is taken as a recognition object, a highly uniform nucleic acid C-reactive protein aptamer probe single layer is formed by combining a freezing-unfreezing method self-assembly technology, and the nucleic acid C-reactive protein aptamer probe single layer has a good linear relationship with a detection electric signal in a C-reactive protein concentration range of 0.5-100 ng / mL; the kit has the properties of high sensitivity, high specificity, rapid response, real-time monitoring, minimally invasive property and the like, is beneficial to rapid detection of C-reactive protein and dynamic monitoring of sepsis course change, and also provides technical support for development of biosensors for biomarker detection in complex media.

A continuous potassium measurement system for determining potassium levels in a user over time is provided. The system includes a continuous potassium sensor (CPS) positioned in interstitial fluid of the user. The system further includes programmed circuitry comprising a processor and a memory where the CPS and programmed circuitry are communicatively coupled. The programmed circuitry is programmed with logic and instructions for completion of the following steps by the programmed circuitry: (i) obtaining data related to the level of potassium in the user from the CPS; (ii) determining the level of potassium in the user from the data obtained in step (i); (iii) storing the level of potassium in the user determined in step (ii) in the memory; and (iv) repeating steps (i) to (iii) to determine and store in the memory potassium levels in a user over time.

The invention provides construction of an electrochemical biosensor based on a fucoidin hydrogel microneedle and application of the electrochemical biosensor in online monitoring of uric acid, and relates to the technical field of biosensors. According to the micro-needle, Gantrez S-97 and PEG are subjected to copolymerization crosslinking to form a hydrogel main body, fucoidin is introduced for blending modification, a three-dimensional network structure is constructed by utilizing a high-temperature esterification reaction for regulating and controlling pH, and the super-expansion hydrogel micro-needle with high swelling property and good biocompatibility is formed. The microneedle can rapidly collect a skin interstitial fluid sample, and then through a screen printing electrode (SPE) platform, carboxylated MWCNTs are used for modifying an electrode and immobilizing uricase to construct an enzyme sensor. Hydrogen peroxide generated by catalyzing uric acid on the surface of the electrode participates in electrochemical reaction, and an output signal is used for real-time detection of uric acid concentration. The device integrates minimally invasive sampling and high-sensitivity electrochemical detection, has the advantages of quick response, simplicity and convenience in operation, good biocompatibility and the like, and is suitable for application scenes of continuous monitoring of uric acid, chronic disease management and the like.

A wearable interstitial fluid (ISF) sensing includes a first patch layer and an electronics module component layer. The electronics module component layer is laminated to the first patch layer to form a patch component and a plurality of microneedles extending from the patch component. The electronics module component layer includes a substrate and a sensor positioned on the substrate. Each microneedle of the plurality of microneedles includes a microneedle base extending from the patch component, a body extending from the microneedle base, and a tip extending from the body. The body defines a slot extending through the first patch layer of the body. The slot defines a first opening and a second opening. The at least one sensor is positioned over the second opening. The first opening, the slot, and the sensor define a channel exposed to the environment. The channel is configured to channel ISF to the sensor.

This disclosure provides a wearable electrochemical biosensor for detecting at least one target analyte in interstitial fluid of a subject, comprising, a microneedle array comprising a highly- crosslinked hydrogel polymer; at least one electrochemical chip comprising at least one transducer surface configured for generating a signal in the presence of the at least one target analyte; and a low crosslinked hydrogel polymer, wherein the low crosslinked hydrogel polymer is configured to couple the microneedle array with the at least one transducer surface of the electrochemical chip. Methods of making and use thereof are also disclosed.